ERBB2 and neoplasm: BluePrint® (BP) is an 80-gene signature that classifies breast tumors into Luminal A, Luminal B, HER2, or Basal molecular subtypes, providing information on tumor behavior, long-term prognosis, and response to systemic therapy.